Breakthrough drug trial aims to save lives from deadly alcohol hepatitis
NCT ID NCT07428538
Summary
This study is testing whether a new drug called larsucosterol can help people with severe alcohol-associated hepatitis survive without needing a liver transplant. Researchers will enroll 350 hospitalized adults with serious liver damage from heavy alcohol use. The main goal is to see if the drug improves survival rates and keeps patients out of the hospital over 90 days.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Liver Institute at Methodist Dallas Medical Center
RECRUITINGDallas, Texas, 75203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.